FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Novid Distributing Unapproved, Misbranded Drug: FDA

FDA warns Northridge, CA-based Novid Group that it is illegally distributing an unapproved and misbranded over-the-counter antihistamine/nasal deconge...

latest-news-card-1
Human Drugs

Vertex Moving Neuropathy Pain Drug to Phase 3

Vertex Pharmaceuticals says it will advance selective NaV1.8 inhibitor VX-548 into pivotal Phase 3 studies based on positive results from its Phase 2 ...

latest-news-card-1
Federal Register

Guide on Advanced Manufacturing Tech

Federal Register notice: FDA makes available a draft guidance entitled Advanced Manufacturing Technologies Designation Program.

latest-news-card-1
Federal Register

Genetic Metabolic Disease Panel Established

Federal Register notice: FDA creates the Genetic Metabolic Diseases Advisory Committee to review and make recommendations on investigational or market...

latest-news-card-1
FDA General

Regulatory Affairs, Foods Program Under Review

FDA says HHS has started reviewing the agencys proposed reorganization for a unified Human Foods Program and a revised Office of Regulatory Affairs.

latest-news-card-1
Human Drugs

HELP Committee OKs EFFECTIVE Opioid Bill

The Senate HELP Committee passes legislation giving FDA additional authority to deny opioid analgesic NDAs.

latest-news-card-1
FDA General

GOP Senators Urge Increase in Foreign Inspections

Nine Republican senators press FDA to increase its foreign inspections of medical product manufacturing facilities.

latest-news-card-1
Biologics

Amgen Files Priority BLA for Lung Cancer

FDA accepts for priority review an Amgen BLA for tarlatamab for treating certain adult patients with advanced small cell lung cancer.

latest-news-card-1
Medical Devices

AdvaMed Faults FDA on Safety 510(k) Guidances

AdvaMed faults FDA for not approving an extension to the comment deadline on three 510(k) guidances issued in September concerning the 2018 Medical De...

Human Drugs

Syndax Pharma Filing NDA for Revumenib

Syndax Pharmaceuticals plans an NDA submission by year end for revumenib, a first-in-class menin inhibitor for treating patients with relapsed/refract...